DK1087975T3 - Epothilon-bikomponenter - Google Patents

Epothilon-bikomponenter

Info

Publication number: DK1087975T3
Authority: DK; Denmark
Prior art keywords: epothilone; bicomponents; xiii; viii; compounds
Prior art date: 1998-06-18

Application number

DK99932700T

Other languages

Danish (da)

English (en)

Inventor

Gerhard Hoefle

Hans Reichenbach

Klaus Gerth

Ingo Hardt

Florenz Sasse

Heinrich Steinmetz

Original Assignee

Biotechnolog Forschung Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-18

Filing date

1999-06-18

Publication date

2003-12-01

1999-06-18 Application filed by Biotechnolog Forschung Gmbh filed Critical Biotechnolog Forschung Gmbh

2003-12-01 Application granted granted Critical

2003-12-01 Publication of DK1087975T3 publication Critical patent/DK1087975T3/da

Links

229930013356 epothilone Natural products 0.000 title abstract 3
150000003883 epothilone derivatives Chemical class 0.000 title 1
GGEZPMGQYPDHAV-VFZIEYQESA-N (-)-Epothilone C1 Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)[C@H]1C GGEZPMGQYPDHAV-VFZIEYQESA-N 0.000 abstract 2
PPADMZQKLQKZMX-STHZYMOHSA-N (-)-Epothilone D1 Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)[C@@H]1C PPADMZQKLQKZMX-STHZYMOHSA-N 0.000 abstract 2
GGEZPMGQYPDHAV-KFVCZWQZSA-N (-)-trans-Epothilone C1 Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)[C@H]1C GGEZPMGQYPDHAV-KFVCZWQZSA-N 0.000 abstract 2
TXXFZHIQMSBVAR-YGFYDDMGSA-N (1r,5s,6s,7r,10s,14s,16s)-14-[(e)-1-(2-ethyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-6,10-dihydroxy-5,7,9,9-tetramethyl-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound S1C(CC)=NC(\C=C(/C)[C@H]2OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@H]3O[C@H]3C2)=C1 TXXFZHIQMSBVAR-YGFYDDMGSA-N 0.000 abstract 2
ROFAAPRTXVOLLR-DFIDMPDGSA-N (4s,7r,8s,9s,11e,13z,16s)-4,8-dihydroxy-5,5,7,9-tetramethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadeca-11,13-diene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)C\C=C\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 ROFAAPRTXVOLLR-DFIDMPDGSA-N 0.000 abstract 2
-1 Epothilone compounds Chemical class 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
XSZHNNYJIPRFJZ-MSYOXSAWSA-N (1r,5s,6s,7r,10s,14s,16s)-6,10-dihydroxy-14-[(e)-3-hydroxy-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-5,7,9,9-tetramethyl-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound OC/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 XSZHNNYJIPRFJZ-MSYOXSAWSA-N 0.000 abstract 1
VKTJUSLRQGGFQY-KKQRBIROSA-N (1r,5s,6s,7r,10s,14s,16s)-6,10-dihydroxy-5,7,9,9-tetramethyl-14-[(e)-1-(2-methyl-1,3-oxazol-4-yl)prop-1-en-2-yl]-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=COC(C)=N1 VKTJUSLRQGGFQY-KKQRBIROSA-N 0.000 abstract 1
HQOMWNCHRWPRQE-PAHOANEJSA-N (1r,5s,6s,7r,10s,14s,16s)-6,10-dihydroxy-5,7,9,9-tetramethyl-14-[(e)-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound C(/[C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HQOMWNCHRWPRQE-PAHOANEJSA-N 0.000 abstract 1
XBRMHTMQENGRNB-FLWVCJORSA-N (1r,5s,6s,7r,9s,10s,14s,16s)-6,10-dihydroxy-5,7,9-trimethyl-14-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)[C@@H](C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 XBRMHTMQENGRNB-FLWVCJORSA-N 0.000 abstract 1
WFXWKMLJLRBVHH-PVYNADRNSA-N (1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(e)-1-(2-methyl-1,3-oxazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=COC(C)=N1 WFXWKMLJLRBVHH-PVYNADRNSA-N 0.000 abstract 1
OAXHQZGPHDPLOS-QHPKQRFUSA-N (4s,11z,14s)-4-hydroxy-5,7-dimethyl-14-[(e)-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]-1-oxacyclotetradec-11-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)C(=O)C(C)CCC\C=C/C[C@H]1\C=C\C1=CSC(C)=N1 OAXHQZGPHDPLOS-QHPKQRFUSA-N 0.000 abstract 1
GGEZPMGQYPDHAV-MXWPJGIKSA-N (4s,5r,7r,8s,9s,13e,16s)-4,8-dihydroxy-5,7,9-trimethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C\C[C@H]1C(\C)=C\C1=CSC(C)=N1 GGEZPMGQYPDHAV-MXWPJGIKSA-N 0.000 abstract 1
PPADMZQKLQKZMX-IJJUSYSYSA-N (4s,5r,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,7,9,13-tetramethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 PPADMZQKLQKZMX-IJJUSYSYSA-N 0.000 abstract 1
GGEZPMGQYPDHAV-BEVKDQKBSA-N (4s,5r,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,7,9-trimethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 GGEZPMGQYPDHAV-BEVKDQKBSA-N 0.000 abstract 1
LUSOGNSOTZPASB-MBJBKAGYSA-N (4s,5r,7r,8s,9s,15z,18s)-4,8-dihydroxy-5,7,9,11,15-pentamethyl-18-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclooctadec-15-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CC(C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 LUSOGNSOTZPASB-MBJBKAGYSA-N 0.000 abstract 1
GGEZPMGQYPDHAV-IAKOSIDASA-N (4s,5s,7r,8s,9s,13e,16s)-4,8-dihydroxy-5,7,9-trimethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C\C[C@H]1C(\C)=C\C1=CSC(C)=N1 GGEZPMGQYPDHAV-IAKOSIDASA-N 0.000 abstract 1
PPADMZQKLQKZMX-MIFDDJEISA-N (4s,5s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,7,9,13-tetramethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 PPADMZQKLQKZMX-MIFDDJEISA-N 0.000 abstract 1
GGEZPMGQYPDHAV-PPIKOIBXSA-N (4s,5s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,7,9-trimethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 GGEZPMGQYPDHAV-PPIKOIBXSA-N 0.000 abstract 1
LUSOGNSOTZPASB-AWGTXPRESA-N (4s,5s,7r,8s,9s,15z,18s)-4,8-dihydroxy-5,7,9,11,15-pentamethyl-18-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclooctadec-15-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CC(C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 LUSOGNSOTZPASB-AWGTXPRESA-N 0.000 abstract 1
OEKZEWLHYAVWRB-GBPKLXHHSA-N (4s,5s,7r,8s,9s,15z,18s)-4,8-dihydroxy-5,7,9,11-tetramethyl-18-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclooctadec-15-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CC(C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 OEKZEWLHYAVWRB-GBPKLXHHSA-N 0.000 abstract 1
OQUHUZWYEYDRMH-JGMJILQLSA-N (4s,7r,8r,9e,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadeca-9,13-diene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)\C(C)=C\CC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 OQUHUZWYEYDRMH-JGMJILQLSA-N 0.000 abstract 1
MVIPGYRWGVEDHK-DQUVJOKZSA-N (4s,7r,8r,9e,13z,16s)-4,8-dihydroxy-5,5,7,9-tetramethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadeca-9,13-diene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)\C(C)=C\CC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 MVIPGYRWGVEDHK-DQUVJOKZSA-N 0.000 abstract 1
BQWMEQIBCWMVHJ-KBOCJPGHSA-N (4s,7r,8s,13z,16s)-4,8-dihydroxy-5,5,7-trimethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)CCCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BQWMEQIBCWMVHJ-KBOCJPGHSA-N 0.000 abstract 1
XHORAZNTIGWOJV-XNHPUFHFSA-N (4s,7r,8s,9s,13z,15s,16r)-4,8,15-trihydroxy-5,5,7,9-tetramethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/[C@H](O)[C@H]1C(\C)=C\C1=CSC(C)=N1 XHORAZNTIGWOJV-XNHPUFHFSA-N 0.000 abstract 1
RPXWIALRKLAACL-PNJPVOQVSA-N (4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-16-[(e)-3-hydroxy-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-5,5,7,9-tetramethyl-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\CO)=C\C1=CSC(C)=N1 RPXWIALRKLAACL-PNJPVOQVSA-N 0.000 abstract 1
QJBTYCVYJKZKMC-GIQCAXHBSA-N (4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(e)-1-(2-methyl-1,3-oxazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=COC(C)=N1 QJBTYCVYJKZKMC-GIQCAXHBSA-N 0.000 abstract 1
RINOSSPYIGLHTK-QJKGZULSSA-N (4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9-tetramethyl-16-[(e)-1-(2-methyl-1,3-oxazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=COC(C)=N1 RINOSSPYIGLHTK-QJKGZULSSA-N 0.000 abstract 1
SZLNOQJINZWMEH-RZFZXLGKSA-N (4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9-tetramethyl-16-[(e)-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1\C=C\C1=CSC(C)=N1 SZLNOQJINZWMEH-RZFZXLGKSA-N 0.000 abstract 1
SHWUXGHQECDXLJ-MUMHOSTJSA-N (4s,7r,8s,9s,15z,18s)-4,8-dihydroxy-5,5,7,9,11,15-hexamethyl-18-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclooctadec-15-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CC(C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 SHWUXGHQECDXLJ-MUMHOSTJSA-N 0.000 abstract 1
ZRXGTLZTTTXSFQ-FMVKWOPFSA-N (4s,7r,8s,9s,15z,18s)-4,8-dihydroxy-5,5,7,9,11-pentamethyl-18-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclooctadec-15-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CC(C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 ZRXGTLZTTTXSFQ-FMVKWOPFSA-N 0.000 abstract 1
MLQWYAQKRLGGTG-ZBUSTYTQSA-N (4s,7r,8s,9s,15z,18s)-4,8-dihydroxy-5,5,7,9-tetramethyl-18-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclooctadec-15-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCCCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 MLQWYAQKRLGGTG-ZBUSTYTQSA-N 0.000 abstract 1
UBEGTFAXEAHJDQ-DZNFWXJJSA-N (4s,8r,9s,13z,16s)-4,8-dihydroxy-5,5,9-trimethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)C[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 UBEGTFAXEAHJDQ-DZNFWXJJSA-N 0.000 abstract 1
XBRMHTMQENGRNB-KHHGMSJLSA-N Epothilone A2 Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)[C@@H]1C XBRMHTMQENGRNB-KHHGMSJLSA-N 0.000 abstract 1
HQOMWNCHRWPRQE-LVYXJCAGSA-N Epothilone A8 Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C=C/c2nc(C)sc2)OC(=O)C[C@H](O)C1(C)C HQOMWNCHRWPRQE-LVYXJCAGSA-N 0.000 abstract 1
XSZHNNYJIPRFJZ-UVQHQIQLSA-N Epothilone A9 Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/CO)OC(=O)C[C@H](O)C1(C)C XSZHNNYJIPRFJZ-UVQHQIQLSA-N 0.000 abstract 1
FBHLXXMDOGRQOQ-FCIKGTDHSA-N Epothilone B10 Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CC)sc2)/C)OC(=O)C[C@H](O)C1(C)C FBHLXXMDOGRQOQ-FCIKGTDHSA-N 0.000 abstract 1
UBEGTFAXEAHJDQ-RTVCTUJYSA-N Epothilone C3 Natural products O=C1C(C)(C)[C@@H](O)CC(=O)O[C@H](/C(=C\c2nc(C)sc2)/C)C/C=C\CCC[C@H](C)[C@H](O)C1 UBEGTFAXEAHJDQ-RTVCTUJYSA-N 0.000 abstract 1
BQWMEQIBCWMVHJ-OOLXDALYSA-N Epothilone C4 Natural products O=C1[C@H](C)[C@@H](O)CCCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BQWMEQIBCWMVHJ-OOLXDALYSA-N 0.000 abstract 1
MVIPGYRWGVEDHK-RVFCSQKWSA-N Epothilone C5 Natural products O=C1[C@H](C)[C@@H](O)/C(/C)=C\CC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C MVIPGYRWGVEDHK-RVFCSQKWSA-N 0.000 abstract 1
ROFAAPRTXVOLLR-QBOGYLEGSA-N Epothilone C6 Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)C/C=C/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C ROFAAPRTXVOLLR-QBOGYLEGSA-N 0.000 abstract 1
XHORAZNTIGWOJV-MBUYUGQOSA-N Epothilone C7 Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\[C@H](O)[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XHORAZNTIGWOJV-MBUYUGQOSA-N 0.000 abstract 1
SZLNOQJINZWMEH-UHFFFAOYSA-N Epothilone C8 Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C=CC1=CSC(C)=N1 SZLNOQJINZWMEH-UHFFFAOYSA-N 0.000 abstract 1
RPXWIALRKLAACL-BKNJOQLSSA-N Epothilone C9 Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/CO)OC(=O)C[C@H](O)C1(C)C RPXWIALRKLAACL-BKNJOQLSSA-N 0.000 abstract 1
OQUHUZWYEYDRMH-UPDIVTRLSA-N Epothilone D5 Natural products O=C1[C@H](C)[C@@H](O)/C(/C)=C\CC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C OQUHUZWYEYDRMH-UPDIVTRLSA-N 0.000 abstract 1
VKTJUSLRQGGFQY-HGYUPSKWSA-N Epothilone G1 Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)oc2)/C)OC(=O)C[C@H](O)C1(C)C VKTJUSLRQGGFQY-HGYUPSKWSA-N 0.000 abstract 1
WFXWKMLJLRBVHH-MOXAZZFHSA-N Epothilone G2 Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)oc2)/C)OC(=O)C[C@H](O)C1(C)C WFXWKMLJLRBVHH-MOXAZZFHSA-N 0.000 abstract 1
RINOSSPYIGLHTK-JRBBLYSQSA-N Epothilone H1 Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)oc2)/C)OC(=O)C[C@H](O)C1(C)C RINOSSPYIGLHTK-JRBBLYSQSA-N 0.000 abstract 1
QJBTYCVYJKZKMC-SDMHVBBESA-N Epothilone H2 Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)oc2)/C)OC(=O)C[C@H](O)C1(C)C QJBTYCVYJKZKMC-SDMHVBBESA-N 0.000 abstract 1
MLQWYAQKRLGGTG-UHFFFAOYSA-N Epothilone I1 Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCCCC=CCC1C(C)=CC1=CSC(C)=N1 MLQWYAQKRLGGTG-UHFFFAOYSA-N 0.000 abstract 1
ZRXGTLZTTTXSFQ-UHFFFAOYSA-N Epothilone I2 Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CC(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 ZRXGTLZTTTXSFQ-UHFFFAOYSA-N 0.000 abstract 1
SHWUXGHQECDXLJ-UHFFFAOYSA-N Epothilone I3 Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CC(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 SHWUXGHQECDXLJ-UHFFFAOYSA-N 0.000 abstract 1
OEKZEWLHYAVWRB-UHFFFAOYSA-N Epothilone I4 Natural products O1C(=O)CC(O)C(C)C(=O)C(C)C(O)C(C)CC(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 OEKZEWLHYAVWRB-UHFFFAOYSA-N 0.000 abstract 1
UYUFFQJDKXXQKP-XPJDJALISA-N Epothilone K Natural products O=C1[C@H](C)[C@@H](O)CC(=O)O[C@H](/C(=C\c2nc(C)sc2)/C)C/C=C(\C)/CCC[C@H]1C UYUFFQJDKXXQKP-XPJDJALISA-N 0.000 abstract 1
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 abstract 1
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Silicon Polymers (AREA)
Dental Preparations (AREA)
Organic Insulating Materials (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)

DK99932700T 1998-06-18 1999-06-18 Epothilon-bikomponenter DK1087975T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19826988A DE19826988A1 (de)	1998-06-18	1998-06-18	Epothilon-Nebenkomponenten
PCT/EP1999/004244 WO1999065913A2 (fr)	1998-06-18	1999-06-18	Constituants secondaires d'epothilone

Publications (1)

Publication Number	Publication Date
DK1087975T3 true DK1087975T3 (da)	2003-12-01

Family

ID=7871162

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99932700T DK1087975T3 (da)	1998-06-18	1999-06-18	Epothilon-bikomponenter

Country Status (11)

Country	Link
US (3)	US6624310B1 (fr)
EP (2)	EP1087975B1 (fr)
JP (1)	JP2002518397A (fr)
AT (1)	ATE248174T1 (fr)
AU (1)	AU757452B2 (fr)
CA (1)	CA2336189A1 (fr)
DE (2)	DE19826988A1 (fr)
DK (1)	DK1087975T3 (fr)
ES (1)	ES2207249T3 (fr)
PT (1)	PT1087975E (fr)
WO (1)	WO1999065913A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ213349A (en) *	1984-09-03	1988-09-29	Macri Vincenzo	Vehicle mounted rotating disc for weeding or cultivating in orchards or vineyards
ES2312695T3 (es) *	1996-11-18	2009-03-01	Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf)	Epotilones e y f.
CA2273083C (fr)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthese d'epothilones, intermediaires utilises dans leur synthese, analogues et utilisations de celles-ci
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en)	1998-05-18	1998-07-15	Ciba Geigy Ag	Organic compounds
DE19826988A1 (de)	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
WO2000031247A2 (fr)	1998-11-20	2000-06-02	Kosan Biosciences, Inc.	Matieres et procedes recombinants destines a la production d'epothilone et de derives d'epothilone
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
DE19908760A1 (de) *	1999-02-18	2000-08-24	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
EP1169038B9 (fr)	1999-04-15	2013-07-10	Bristol-Myers Squibb Company	Inhibiteurs cycliques de proteine tyrosine kinase
US6589968B2 (en)	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
US6489314B1 (en)	2001-04-03	2002-12-03	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
WO2001092255A2 (fr) *	2000-05-26	2001-12-06	Kosan Biosciences, Inc.	Derives d'epothilone, procedes de production et methodes d'utilisation
GB0029895D0 (en) *	2000-12-07	2001-01-24	Novartis Ag	Organic compounds
US6893859B2 (en)	2001-02-13	2005-05-17	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
US20030176368A1 (en) *	2001-09-06	2003-09-18	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
TW200303202A (en) *	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
US6900331B2 (en) *	2002-03-01	2005-05-31	University Of Notre Dame	Derivatives of epothilone B and D and synthesis thereof
SI1483251T1 (sl)	2002-03-12	2010-03-31	Bristol Myers Squibb Co	C cian epotilonski derivati
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (fr)	2002-08-23	2010-05-19	Sloan-Kettering Institute For Cancer Research	Synthèse d'épothilones, intermédiaires, analogues et leurs utilisations
US7384964B2 (en) *	2002-08-23	2008-06-10	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) *	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004045518A2 (fr)	2002-11-15	2004-06-03	Bristol-Myers Squibb Company	Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
GB0230024D0 (en) *	2002-12-23	2003-01-29	Novartis Ag	Organic compounds
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
EP1824458A1 (fr) *	2004-11-18	2007-08-29	Bristol-Myers Squibb Company	Bille enrobee de keratine comprenant de l'epothilone ou un analogue d'epothilone, ainsi que preparation et administration de cette bille
AR052142A1 (es) *	2004-11-18	2007-03-07	Bristol Myers Squibb Co	Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
US7754850B2 (en)	2005-02-11	2010-07-13	University Of Southern California	Chimeric disintegrin domain
EP2029156A4 (fr) *	2006-05-01	2010-07-21	Univ Southern California	Polythérapie pour traiter le cancer
JP2010511408A (ja)	2006-12-04	2010-04-15	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
EP2152717A1 (fr)	2007-05-25	2010-02-17	Bristol-Myers Squibb Company	Procedes de fabrication de composes et d'analogues d'epothilone
US8802394B2 (en)	2008-11-13	2014-08-12	Radu O. Minea	Method of expressing proteins with disulfide bridges with enhanced yields and activity
JP5889337B2 (ja)	2011-01-20	2016-03-22	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	Ｍｒｉマーカー、送達および抜取りシステムならびにこれらの製造方法および使用方法
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
WO2014075391A1 (fr)	2012-11-17	2014-05-22	北京市丰硕维康技术开发有限责任公司	Composé du platine et de dérivé de l'acide malonique ayant un groupe partant contenant un groupe amino ou alkylamino

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4183099B2 (ja) *	1995-11-17	2008-11-19	ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ）	エポチロンｃおよびｄ、製造法ならびに組成物
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
AU716610B2 (en) *	1996-08-30	2000-03-02	Novartis Ag	Method for producing epothilones, and intermediate products obtained during the production process
ES2312695T3 (es) *	1996-11-18	2009-03-01	Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf)	Epotilones e y f.
CA2273083C (fr)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthese d'epothilones, intermediaires utilises dans leur synthese, analogues et utilisations de celles-ci
US6204388B1 (en) *	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) *	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en) *	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
JP2001513098A (ja) *	1997-02-25	2001-08-28	ゲゼルシャフトフュアバイオテクノロギッシェフォーシュンクエムベーハー（ゲーベーエフ）	側鎖を修飾したエポチロン
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
CA2322157C (fr)	1998-02-25	2012-05-29	Sloan-Kettering Institute For Cancer Research	Synthese d'epothilones, de leurs intermediaires et de leurs analogues
US6399638B1 (en) *	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
DE19826988A1 (de)	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
WO2000000485A1 (fr)	1998-06-30	2000-01-06	Schering Aktiengesellschaft	Derives d'epothilone, leur procede de production, produits intermediaires et leur utilisation pharmaceutique
WO2000031247A2 (fr) *	1998-11-20	2000-06-02	Kosan Biosciences, Inc.	Matieres et procedes recombinants destines a la production d'epothilone et de derives d'epothilone
US5969159A (en)	1999-02-16	1999-10-19	Great Lakes Chemical Corporation	Synthesis of cyclopentyl 2-thienyl ketone tiletamine and tiletamine acid addition salts such as tiletamine hydrochloride
CA2422500A1 (fr) *	2000-09-22	2003-03-18	Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)	Triazolo-epothilones
NZ527557A (en) *	2001-02-27	2005-05-27	Biotechnolog Forschung Gmbh	Degradation of epothilones and ethynyl substituted epothilones

1998
- 1998-06-18 DE DE19826988A patent/DE19826988A1/de not_active Withdrawn
1999
- 1999-06-18 EP EP99932700A patent/EP1087975B1/fr not_active Expired - Lifetime
- 1999-06-18 DK DK99932700T patent/DK1087975T3/da active
- 1999-06-18 CA CA002336189A patent/CA2336189A1/fr not_active Abandoned
- 1999-06-18 JP JP2000554738A patent/JP2002518397A/ja not_active Withdrawn
- 1999-06-18 AT AT99932700T patent/ATE248174T1/de not_active IP Right Cessation
- 1999-06-18 ES ES99932700T patent/ES2207249T3/es not_active Expired - Lifetime
- 1999-06-18 DE DE59906782T patent/DE59906782D1/de not_active Expired - Lifetime
- 1999-06-18 WO PCT/EP1999/004244 patent/WO1999065913A2/fr not_active Ceased
- 1999-06-18 EP EP02022332A patent/EP1275648A1/fr not_active Withdrawn
- 1999-06-18 US US09/719,932 patent/US6624310B1/en not_active Expired - Lifetime
- 1999-06-18 PT PT99932700T patent/PT1087975E/pt unknown
- 1999-06-18 AU AU48995/99A patent/AU757452B2/en not_active Ceased
2003
- 2003-06-06 US US10/457,098 patent/US20040049051A1/en not_active Abandoned
2006
- 2006-02-15 US US11/354,769 patent/US7235669B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2336189A1 (fr)	1999-12-23
US6624310B1 (en)	2003-09-23
DE19826988A1 (de)	1999-12-23
EP1087975B1 (fr)	2003-08-27
JP2002518397A (ja)	2002-06-25
US20060142584A1 (en)	2006-06-29
WO1999065913A3 (fr)	2000-04-20
US20040049051A1 (en)	2004-03-11
WO1999065913A2 (fr)	1999-12-23
EP1275648A1 (fr)	2003-01-15
US7235669B2 (en)	2007-06-26
PT1087975E (pt)	2004-01-30
ATE248174T1 (de)	2003-09-15
DE59906782D1 (de)	2003-10-02
AU4899599A (en)	2000-01-05
AU757452B2 (en)	2003-02-20
ES2207249T3 (es)	2004-05-16
EP1087975A2 (fr)	2001-04-04

Publication	Publication Date	Title
DK1087975T3 (da)	2003-12-01	Epothilon-bikomponenter
ATE364198T1 (de)	2007-06-15	1,3-dihydro-1-oxo-2h-indenderivat
MY138525A (en)	2009-06-30	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CO4820391A1 (es)	1999-07-28	Compuestos hipolipidemicos de benzotiazepina
DK1385514T5 (da)	2009-03-09	Spiroinden- og spiroindanforbindelser
TR200800474T2 (tr)	2008-04-21	Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
CY2007024I2 (el)	2010-07-28	Kαινοφανη παραγωγα 3.3-διαφαινυλοπροπυλινων
EP0722731A4 (fr)	1998-03-04	Remede contre la degenerescence spino-cerebelleuse
AU5704099A (en)	2000-03-27	Process for making 2- (2,4- dihydroxyphenyl) or 2- (2,4- dialkoxyphenyl)- 4,6- bisaryl- 1,3,5- triazines
FI953710A0 (fi)	1995-08-03	Uusia pyrrolokarbatsoleja
DE60020355D1 (de)	2005-06-30	Duft Vorläufer
DK0755922T3 (da)	2000-11-13	22-Thiavitamin D3-derivat
AU2002365378A1 (en)	2003-06-10	Process for preparing 3,3',6,6'-tetraalkyl-2,2'-biphenols and 3,3',6,6'-tetraalkyl-5,5'-dihalo-2,2'-biphenols
GB0019124D0 (en)	2000-09-27	Novel process
EP1203763A3 (fr)	2004-01-14	Beta-hydroxyalkylamides, leur procédé de fabrication et leur application
DE69906243T2 (de)	2004-01-29	2-Indanmethanolderivate und ihre Verwendung als Riechstoffe
DE50011888D1 (de)	2006-01-26	Tetracyclische Acetale
HRP20031068B1 (en)	2011-12-31	Chloromethylation of thiophene
DE69706950D1 (de)	2001-10-31	Furoindolizine
AU6115998A (en)	1998-09-18	Compositions for treatment or prevention of prostate cancer
AU2407597A (en)	1998-11-24	Eyedrops
RU2000116861A (ru)	2002-03-27	Стимулятор роста яровой пшеницы
AU2003248059A1 (en)	2004-02-09	NOVEL Alpha-KETOAMIDE DERIVATIVE AND USE THEREOF
AU1465895A (en)	1995-08-01	7-thiaprostaglandins and process for producing the same
IT1318465B1 (it)	2003-08-25	Processo per la preparazione di decaidro-2a, 4a,6a,8a-tetraazaciclopent(fg)acenaftilene e derivati funzionalizzati.